

AGENDA

Tuesday, October 23, 2018

FDA & MHRA Good Clinical Practice Workshop: *Data Integrity in Global Clinical Trials – Are We There Yet?*

8:00 AM	Registration Opens
8:50 - 9:00 AM	Administrative Announcements
9:00 - 9:10 AM	<p>Welcome & Opening Remarks</p> <p>David Burrow, Pharm.D, J.D., Director, Office of Scientific Investigations CDER FDA</p>
9:10 - 9:25 AM	<p>Key Note Speaker</p> <p>Robert Temple, M.D., Deputy Director for Clinical Science CDER FDA</p>
9:25 - 10:35 AM	<p>Session 1 – Data Integrity from International Perspectives (Moderator – Ni Khin)</p> <p><i>Background and Purpose of Collaboration (15 min)</i></p> <p>Ni Khin, M.D., Director, Division of Clinical Compliance Evaluation (DCCE), Office of Scientific Investigations (OSI), CDER, FDA</p> <p>Gail Francis, Expert GCP Inspector, MHRA</p> <p><i>Quality Management System/Quality by Design (QMS/QbD) (15 min)</i></p> <p>Jean Mulinde, M.D., Senior Advisor, DCCE/OSI, CDER/FDA</p> <p><i>Overview of Data Integrity (20 min)</i></p> <p>Gail Francis, Expert GCP Inspector, MHRA</p> <p><i>Good Clinical Practice Assessment of Data Reliability in Registration Trials (20 min)</i></p> <p>Kassa Ayalew, M.D., M.P.H., Branch Chief, DCCE/OSI, CDER/FDA</p>
10:35 - 10:50 AM	B R E A K
10:50 - 12:05 PM	<p>Session 2: Data Management (Moderator – Kassa Ayalew)</p> <p><i>Control and Quality of Clinical Data (55 min)</i></p> <p>Andy Fisher, Lead Senior GCP Inspector, MHRA</p> <p><i>The Data Management Plan – Pulling It All Together (20 min)</i></p> <p>Cynthia Kleppinger, M.D., Senior Medical Officer, DCCE/OSI, CDER/FDA</p>
12:05 - 12:30 PM	Q&A and Panel Discussion
12:30 - 1:30 PM	L U N C H (Self-Pay)
1:30 - 2:45 PM	<p>Session 3: Controlling Bias: The Study Blind (Moderator – Cynthia Kleppinger)</p> <p><i>Unblinding – Let Me Count the Ways (55 min)</i></p> <p>Gail Francis, Expert GCP Inspector, MHRA</p> <p>Jean Mulinde, M.D., Senior Advisor, DCCE/OSI, CDER/FDA</p> <p><i>Blinding of Bioequivalence Trials (20 min)</i></p> <p>Seongeun (Julia) Cho, Ph.D., Director, Division of Generic Drug Bioequivalence Evaluation, Office of Study Integrity and Surveillance (OSIS), CDER/FDA</p>
2:45 - 3:00 PM	B R E A K
3:00 - 4:00 PM	<p>Session 4: Know Your Audit Trails (Moderator - Jean Mulinde)</p> <p><i>Design and Effective Use of Audit Trails (45 min)</i></p> <p>Stephen Vinter, Operations Manager GLPMA & Laboratories Group, MHRA</p> <p><i>A Case Example of the Review of Audit Trails in GCP Inspections (15 min)</i></p> <p>Phillip Kronstein, M.D., Team Lead, DCCE/OSI, CDER/FDA</p>
4:00 - 4:55 PM	Q&A and Panel Discussion
4:55 - 5:00 PM	Wrap-Up - Discuss Day 2 Case Study Expectations
5:00 - 6:30 PM	Networking Opportunity - TDCC Building 4 Lounge (Self-Pay)



AGENDA

Wednesday, October 24, 2018

FDA & MHRA Good Clinical Practice Workshop: *Data Integrity in Global Clinical Trials – Are We There Yet?*

9:00 - 9:05 AM Introductions - Case Studies

9:05 - 10:35 AM Session 1 - Case Studies on BE/GCP (Moderator - Cynthia Kleppinger)

Vendor selection

Sean Kassim, Ph.D., Director, Office of Study Integrity and Surveillance, CDER/FDA
Stephen Vinter, Operations Manager GLPMA & Laboratories Group, MHRA

Unblinding

Charles Bonapace, Pharm.D., Director, Division of New Drug Bioequivalence Evaluation, OSIS, CDER/FDA
Gail Francis, Expert GCP Inspector, MHRA
Jean Mulinde, M.D., Senior Advisor, DCCE/OSI, CDER/FDA

10:35-10:50 AM

BREAK

10:50 - 12:20 PM Session 2 - Case Studies on BE/GCP (Moderator - Sean Kassim)

Audit Trail

Arindam Dasgupta, Ph.D., Deputy Director, DND/OSIS, CDER/FDA
Phillip Kronstein, M.D., Team Lead, DCCE/OSI, CDER/FDA
Ruben Ayala, Pharm.D., Team Lead, DND/OSIS, CDER/FDA

Data Management

Seongeun (Julia) Cho, Ph.D., Director, DGD/OSIS, CDER/FDA
Andy Fisher, Lead Senior GCP Inspector, MHRA
Cynthia Kleppinger, M.D., Senior Medical Officer, DCCE/OSI, CDER/FDA

12:20 - 12:50 PM Q & A Session

12:50 - 1:00 PM Closing Remarks

Please keep up to date with future SBIA events by visiting:

SBIAevents.com

